BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

963 related articles for article (PubMed ID: 18463448)

  • 21. The two-compound formulation of calcipotriol and betamethasone dipropionate for treatment of moderately severe body and scalp psoriasis - an introduction.
    Freeman K
    Curr Med Res Opin; 2011 Jan; 27(1):197-203. PubMed ID: 21142834
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of safety and efficacy between calcipotriol plus betamethasone dipropionate gel and calcipotriol scalp solution as long-term treatment for scalp psoriasis in Chinese patients: a national, multicentre, prospective, randomized, active-controlled phase 4 trial.
    Liu L; Zhang C; Wang J; Chen K; Ding Y; Yan G; Lu Q; Li W; Fang H; Cheng H; Zhang J; He Y; Zhu W; Lu Y; Huang J; Pan W; Li M; Cao S; Li S; Han X; He L; Chen Y; Zheng M
    Eur J Dermatol; 2020 Oct; 30(5):580-590. PubMed ID: 33052103
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of a psoriasis plaque test in the development of a gel formulation of calcipotriol and betamethasone dipropionate for scalp psoriasis.
    Queille-Roussel C; Hoffmann V; Enevold A; Ganslandt C
    J Dermatolog Treat; 2013 Aug; 24(4):250-4. PubMed ID: 22103604
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Calcipotriene plus betamethasone dipropionate topical suspension for the treatment of mild to moderate psoriasis vulgaris on the body: a randomized, double-blind, vehicle-controlled trial.
    Menter A; Gold LS; Bukhalo M; Grekin S; Kempers S; Boyce BM; Ganslandt C; Villumsen J; Lebwohl M
    J Drugs Dermatol; 2013 Jan; 12(1):92-8. PubMed ID: 23377334
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Calcipotriol and betamethasone dipropionate (Dovobet, Daivobet): a new formulation for the treatment of psoriasis.
    Poulin Y
    Skin Therapy Lett; 2002 Jun; 7(6):1-3. PubMed ID: 12223976
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pooled safety analysis of calcipotriol plus betamethasone dipropionate gel for the treatment of psoriasis on the body and scalp.
    Kragballe K; van de Kerkhof P
    J Eur Acad Dermatol Venereol; 2014 May; 28 Suppl 2():10-21. PubMed ID: 24684739
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 1% pimecrolimus, 0.005% calcipotriol, and 0.1% betamethasone in the treatment of intertriginous psoriasis: a double-blind, randomized controlled study.
    Kreuter A; Sommer A; Hyun J; Bräutigam M; Brockmeyer NH; Altmeyer P; Gambichler T
    Arch Dermatol; 2006 Sep; 142(9):1138-43. PubMed ID: 16983001
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The DESIRE study--psoriasis patients' satisfaction with topical treatment using a fixed combination of calcipotriol and betamethasone dipropionate in daily clinical practice.
    Claréus BW; Houwing R; Sindrup JH; Wigchert S
    Eur J Dermatol; 2009; 19(6):581-5. PubMed ID: 19726275
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of calcipotriene plus betamethasone dipropionate topical suspension in the treatment of extensive scalp psoriasis in adolescents ages 12 to 17 years.
    Eichenfield LF; Ganslandt C; Kurvits M; Schlessinger J
    Pediatr Dermatol; 2015; 32(1):28-35. PubMed ID: 25412565
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Consensus on the use of the fixed combination calcipotriol/betamethasone dipropionate in the treatment of plaque psoriasis.
    Girolomoni G; Vena GA; Ayala F; Cannavò SP; De Pità O; Chimenti S; Peserico A
    G Ital Dermatol Venereol; 2012 Dec; 147(6):609-24. PubMed ID: 23149707
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of nail psoriasis with a two-compound formulation of calcipotriol plus betamethasone dipropionate ointment.
    Rigopoulos D; Gregoriou S; Daniel Iii CR; Belyayeva H; Larios G; Verra P; Stamou C; Kontochristopoulos G; Avgerinou G; Katsambas A
    Dermatology; 2009; 218(4):338-41. PubMed ID: 19212110
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy, safety and quality of life of calcipotriol/betamethasone dipropionate (Dovobet) versus calcipotriol (Daivonex) in the treatment of psoriasis vulgaris: a randomized, multicentre, clinical trial.
    Saraceno R; Andreassi L; Ayala F; Bongiorno MR; Giannetti A; Lisi P; Martini P; Peris K; Peserico A; Chimenti S
    J Dermatolog Treat; 2007; 18(6):361-5. PubMed ID: 17934937
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of guttate psoriasis with a new two-compound product containing calcipotriol and betamethasone dipropionate.
    Vakirlis E; Kastanis A; Lazaridou E; Loannides D; Chrysomallis F
    Int J Clin Pharmacol Res; 2005; 25(4):165-8. PubMed ID: 16402632
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spotlight on calcipotriene/betamethasone dipropionate in psoriasis vulgaris of the trunk, limbs, and scalp.
    McCormack PL
    Am J Clin Dermatol; 2011 Dec; 12(6):421-4. PubMed ID: 21967117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of psoriasis vulgaris with the two-compound product calcipotriol/betamethasone dipropionate followed by different formulations of calcipotriol.
    Cassano N; Miracapillo A; Coviello C; Loconsole F; Bellino M; Vena GA
    Clin Drug Investig; 2006; 26(4):227-33. PubMed ID: 17163256
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pulsed dye laser versus treatment with calcipotriol/betamethasone dipropionate for localized refractory plaque psoriasis: effects on T-cell infiltration, epidermal proliferation and keratinization.
    Bovenschen HJ; Erceg A; Van Vlijmen-Willems I; Van De Kerkhof PC; Seyger MM
    J Dermatolog Treat; 2007; 18(1):32-9. PubMed ID: 17365265
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: a randomized comparison of efficacy and safety in subjects with scalp psoriasis.
    Reygagne P; Mrowietz U; Decroix J; de Waard-van der Spek FB; Acebes LO; Figueiredo A; Caputo R; Poncet M; Arsonnaud S
    J Dermatolog Treat; 2005 Feb; 16(1):31-6. PubMed ID: 15897165
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of the two-compound formulation calcipotriol and betamethasone dipropionate compared with commonly used topical treatments in the management of moderately severe plaque psoriasis in Scotland.
    Bottomley JM; Auland ME; Morais J; Boyd G; Douglas WS
    Curr Med Res Opin; 2007 Aug; 23(8):1887-901. PubMed ID: 17610804
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and local safety of a calcipotriol/ betamethasone dipropionate ointment in elderly patients with psoriasis vulgaris.
    Parslew R; Traulsen J
    Eur J Dermatol; 2005; 15(1):37-9. PubMed ID: 15701591
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial.
    Kircik LH
    J Drugs Dermatol; 2011 Aug; 10(8):878-82. PubMed ID: 21818509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 49.